The Wall Street Journal says the U.S. Food and Drug Administration is doing a reassessment of Avandia – a diabetes drug manufactured by GlaxoSmithKline that was once regarded as a blockbuster in the pharmaceutical market.
In 2007, a study linked Avandia to heart attacks. In 2010, the FDA imposed restrictions requiring the manufacturer to advise patients of the risk information. Health-care providers must also provide documentation verifying that the risk information ...
continue reading...
A lawsuit has gone to jury trial in Los Angeles, alleging that the manufacturer of the diabetes drug Actos concealed its cancer risks, Bloomberg reports.
The plaintiff’s lawyer claims that internal studies by Takeda, Asia’s biggest drug manufacturer, uncovered Actos’s links to bladder cancer as early as 2004. But the company didn’t alert U.S. regulators until seven years later, in order to protect more than $1.6 billion in annual sales.
Other diabetes ...
continue reading...
The U.S. Food and Drug Administration has approved Johnson & Johnson’s drug Invokana, which will be used to treat type 2 diabetes.
According to the New York Times, Invokana is the first of a new class of diabetes medication. It causes blood sugar to be excreted in the urine, as opposed to many other drugs on the market that work by affecting the supply or use of insulin.
Last year, the FDA ...
continue reading...
A story in Forbes says medical professionals and industry analysts are both keeping a close eye on Johnson & Johnson’s Invokana, newly approved by the U.S. Food and Drug Administration. It’s the first to be approved among a new class of medications that treat type 2 diabetes by reducing blood sugar, rather than affecting the supply or use of insulin.
While the drug has the potential to be a blockbuster for ...
continue reading...
A newly approved diabetes drug from Johnson & Johnson may have the potential to be very profitable, given skyrocketing diabetes rates in the Unites States. But a story on the blog Seeking Alpha cautions investors against being too optimistic, given the disappointing results of other diabetes drugs that have gone on the market.
The story mentions GlaxoSmithKline’s Avandia, which has been linked to increased fatalities from heart disease, and is now ...
continue reading...
The U.S. Food and Drug Administration is examining unpublished findings by a group of academic researchers, which suggest a potential link between newer diabetes drugs and pancreatic cancer.
Among the drugs being investigated are Merck’s Januvia and Bristol-Myers Squibb’s Byetta, Bloomberg reports.
Researchers called for an investigation after publishing an analysis of insurance records in the medical journal JAMA Internal Medicine. That analysis concluded that diabetics hospitalized with pancreatitis were twice as ...
continue reading...
